

American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone: 202-776-0544 | Fax 202-776-0545 bloodadvances@hematology.org

## Impact of Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation in Non-Hodgkin Lymphoma

Tracking no: ADV-2023-011040R1

Chijioke Nze (The University of Texas MD Anderson Cancer Center, United States) Clark Andersen (The University of Texas MD Anderson Cancer Center, United States) Amy Ayers (The University of Texas MD Anderson Cancer Center, United States) Jason Westin (The University of Texas M.D. Anderson Cancer Center, United States) Michael Wang (The University of Texas M.D. Anderson Cancer Center, United States) Swaminathan Iyer (MD Anderson Cancer Center, United States) Sairah Ahmed (University of Texas, MD Anderson Cancer Center, United States) Chelsea Pinnix (MD Anderson Cancer Center, United States) Francisco Vega (The University of Texas MD Anderson Cancer Center, United States) Lynne Nguyen (The University of Texas MD Anderson Cancer Center, United States) Lorna McNeill (The University of Texas MD Anderson Cancer Center, United States) Lorna McNeill (The University of Texas MD Anderson Cancer Center, United States) Lorna McNeill (The University of Texas MD Anderson Cancer Center, United States) Lorna McNeill (The University of Texas MD Anderson Cancer Center, United States) Loretta Nastoupil (UT MD Anderson Cancer Center, United States) Kehe Zhang (Center for Spatial Temporal Modeling for Applications in Population Sciences, United States) Cici Bauer (Center for Spatial Temporal Modeling for Applications in Population Sciences, United States) Christopher Flowers (UT MD Anderson Cancer Center, Afghanistan)

#### Abstract:

Prior studies have demonstrated that certain populations including older patients, racial/ethnic minority groups, and women are underrepresented in clinical trials. We performed a retrospective analysis of patients with Non-Hodgkin Lymphoma (NHL) seen at MD Anderson Cancer Center (MDACC) to investigate the association between trial participation, race/ethnicity, travel distance and neighborhood socioeconomic status (nSES). Using patient addresses, we ascertained nSES variables on educational attainment, income, poverty, racial composition and housing at the census tract (CT) level. We also performed geospatial analysis to determine the geographic distribution of clinical trial participants and distance from patient residence to MDACC. We examined 3146 consecutive adult patients with NHL seen between January 2017 and December 2020. The study cohort was predominantly male and non-Hispanic white (NHW). The most common insurance types were private insurance and Medicare; only 1.1% of patients had Medicaid. There was a high overall participation rate of 30.5% with 20.9% enrolled in therapeutic trials. In univariate analyses, lower participation rates were associated with lower nSES including higher poverty rates and living in crowded households. Racial composition of CT was not associated with differences in trial participation. In multivariable analysis, trial participation varied significantly by histology and participation declined nonlinearly with age in the overall, follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) models. In the DLBCL subset, Hispanic patients had lower odds of participation than Whites (odds ratio 0.36 [95% confidence interval 0.21 - 0.62 p=0.001). In our large academic cohort, race, gender, insurance type, and nSES were not associated with trial participation, whereas age and diagnosis were.

Conflict of interest: No COI declared

COI notes:

Preprint server: No;

Author contributions and disclosures: C.N, and , M.B., and C.R.F. performed the literature search and refinements; and R.J.L., M.B., C.S.D., and C.R.F. designed the research, contributed to the search terms, analyzed the data, and wrote the paper.

#### Non-author contributions and disclosures: No;

Agreement to Share Publication-Related Data and Data Sharing Statement: Data can be shared with those who request it. Data can be obtained by emailing to the corresponding author

Clinical trial registration information (if any):

# Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma

5

Chijioke Nze<sup>1\*</sup>, Clark R. Andersen<sup>2</sup>, Amy A. Ayers<sup>1</sup>, Jason Westin<sup>1</sup>, Michael Wang<sup>1</sup>, Swaminathan Iyer<sup>1</sup>, Sairah Ahmed<sup>1</sup>, Chelsea
 Pinnix<sup>3</sup>, Francisco Vega<sup>4</sup>, Lynne Nguyen<sup>5</sup>, Lorna McNeil<sup>5</sup>, Loretta J. Nastoupil<sup>1</sup>, Kehe Zhang<sup>6,7</sup>, Cici X. Bauer<sup>6,7</sup> and Christopher R.
 Flowers<sup>1</sup>

 <sup>1</sup>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston Texas <sup>2</sup>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston Texas, <sup>3</sup>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston Texas, <sup>4</sup>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston Texas., <sup>5</sup>Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston Texas, <sup>6</sup>Department of Biostatistics and Data Science, University of Texas Health Science Center in Houston (UTHealth) School of Public Health, <sup>7</sup>Center for Spatial-Temporal Modeling for Applications in Population Sciences, University of Texas Health Science Center in Houston (UTHealth) School of Public Health

16 **\*Corresponding Author:** Chijioke Nze, MD, MPH (email: ccnze@mdanderson.org; Address: 1515 Holcombe Blvd, Houston Tx

- 17 77006; Phone number: 8327291752)
- 18
- 19 Data can be shared with those who request it. Data can be obtained by emailing to the corresponding author
- 20
- 21 Word count:
- 22 Text: 4794
- 23 Abstract: 256
- 24 reference count: 58
- 25
- 26

2

3

5

6

#### 4 Key points

- In center with a robust clinical trial infrastructure and a strong culture of trials, clinical trial enrollment is high across demographics
- 7 In our cohort, race, gender, socioeconomic variables were not predictors of trial participation, whereas age and diagnosis were predictive 8

#### Abstract 9

10 Prior studies have demonstrated that certain populations including older patients, racial/ethnic minority groups, and women are underrepresented in clinical trials. We performed a retrospective analysis of patients with Non-Hodgkin Lymphoma (NHL) seen at MD 11 Anderson Cancer Center (MDACC) to investigate the association between trial participation, race/ethnicity, travel distance and 12 neighborhood socioeconomic status (nSES). Using patient addresses, we ascertained nSES variables on educational attainment, 13 income, poverty, racial composition and housing at the census tract (CT) level. We also performed geospatial analysis to determine 14 the geographic distribution of clinical trial participants and distance from patient residence to MDACC. We examined 3146 15 consecutive adult patients with NHL seen between January 2017 and December 2020. The study cohort was predominantly male 16 17 and non-Hispanic white (NHW). The most common insurance types were private insurance and Medicare; only 1.1% of patients had Medicaid. There was a high overall participation rate of 30.5% with 20.9% enrolled in therapeutic trials. In univariate analyses, lower 18 participation rates were associated with lower nSES including higher poverty rates and living in crowded households. Racial 19 composition of CT was not associated with differences in trial participation. In multivariable analysis, trial participation varied 20 significantly by histology and participation declined nonlinearly with age in the overall, follicular lymphoma and diffuse large B-cell 21 lymphoma (DLBCL) models. In the DLBCL subset, Hispanic patients had lower odds of participation than Whites (odds ratio 0.36 22 [95% confidence interval 0.21 - 0.62 p=0.001). In our large academic cohort, race, gender, insurance type, and nSES were not 23 associated with trial participation, whereas age and diagnosis were. 24 25 26

27

28 29

30

31 32

- 2
- 3

#### 4 Background:

Non-Hodgkin lymphoma (NHL) is the seventh most common cancer, and the ninth leading cause of cancer death for both men and 5 6 women in the United States (US). In 2023, an estimated 80,550 people in the US will be diagnosed with NHL, and 20,180 will die from NHL.<sup>1</sup> Although the incidence of NHL in the United States has decreased and survival has improved in recent years,<sup>2</sup> disparities 7 on the basis of race, gender, age, insurance status, demographic location, socioeconomic status (SES), and other sociodemographic 8 characteristics remain.<sup>3-9</sup> There have been tremendous advancements in NHL therapies and outcomes in large part due to clinical 9 trials, which are critical for advancing our understanding of cancer biology, evaluating the efficacy of novel treatments, and informing 10 treatment decisions. Older individuals, certain minority groups (specifically black and Hispanic patients), and women are recognized 11 to be underrepresented in oncology clinical trials.<sup>10,11</sup> A recent analysis of randomized controlled trials, which were crucial for the 12 Federal Food and Drug Administration (FDA) approval of drugs for lymphoma treatment, has highlighted significant disparities in 13 participant representation. Black patients, who make up 10.7% of Non-Hodgkin Lymphoma (NHL) cases according to Surveillance, 14 Epidemiology, and End Results Program (SEER) statistics, were only 2.8% of the participants in these trials. Similarly, Hispanic 15 patients, despite constituting 17.1% of NHL patients, were underrepresented at 5.4% in these clinical trials.<sup>12</sup> Under-representation of 16 these groups in trials is detrimental to both these patient populations that do not receive equal access to novel therapies and to the 17 trials that evaluate new approaches in subjects who do not accurately reflect the patient populations where the interventions are 18 intended to be applied. In response to these findings, the US FDA now requires those seeking approval for late-stage clinical trials to 19 submit a plan to ensure diversity among trial participants.<sup>13</sup> 20 21

Understanding the influence of social context on clinical trial enrollment is vital to identify potential areas where tailored interventions 22 23 can effectively address participation barriers as well as identify patient populations at risk of underrepresentation. Individual level data on socioeconomic factors such as household income, educational attainment, employment status are not prospectively 24 collected and/or consistently documented, making it difficult to assess the effects of these variables on health outcomes and 25 26 healthcare utilization. Neighborhood-level socioeconomic measures based on patient addresses may approximate individual level effects while also capturing contextual effects of an individual's environment.<sup>6,9,14</sup> The objective of our study was to investigate the 27 28 associations between clinical trial participation patterns, patient demographics, and neighborhood socioeconomic status (nSES) factors determined by place of residence among patients with NHL seen at the University of Texas MD Anderson Cancer Center 29 (MDACC) located in Houston, Texas. The Department of Lymphoma and Myeloma at MDACC is one of the largest multidisciplinary 30 programs for lymphoma and myeloma with a robust portfolio of lymphoma clinic trials as well as programs to support clinical trial 31 enrollment such as dedicated research nurse coordinator, patient navigators and financial assistance programs. Although this study 32 reflects the practice of a large single center, this is to our knowledge the first study to apply this approach for a comprehensive 33 evaluation of clinical enrollment in patients with NHL across subtypes. 34

## 2 Methods:

3 Data source and study populations:

We performed a retrospective cohort study of adult patients with NHL seen in The MDACC Department of Lymphoma and Myeloma in Houston, Texas. Our cohort consisted of patients with age greater than18 years who had a first visit at MDACC between January 2017 and December 2020. All patients without verified NHL histology were excluded. We utilized a MDACC cancer registry that records consecutive patients with newly diagnosed invasive cancer identified at our institution and the department Lymphoma Outcomes Database (LOD) that records all patients with lymphoma seen at MDACC. The LOD includes data extracted directly from patient charts with quality assurance checks by trained data abstractors. We identified patients who participated in clinical trials based on clinical trial enrollment tracked for the Cancer Center Support Grant (CCSG) report.

11

#### 12 Outcomes and clinical trials definitions

- 13
- 14 The primary outcome of this study was the clinical trial participation, defined as enrollment and participation in any clinical trial
- including both interventional and non-interventional studies, from January 2017 to December 2020.
- 16 Clinical trials were any investigational studies performed prospectively involving human subjects. Clinical trials are broadly
- 17 categorized as interventional or non-interventional. Non-interventional trials were largely observational and involved no prospective
- 18 intervention or alteration in the status of the participants. Interventional trials were trials in which participants were prospectively
- 19 assigned to receive a specific intervention. This assignment could have been random for some studies. Participants received
- 20 diagnostic, treatment, behavioral, or other types of interventions. Interventional therapeutic trials involved specific therapies or
- 21 procedures with therapeutic intent. Interventional non-therapeutic trials involved interventions without a specific therapeutic purpose,
- 22 including diagnostic imaging or tissue sampling performed without therapeutic components.
- 23
- 24 Demographics and Neighborhood socioeconomic variables

Patient demographic information at the time of diagnosis was obtained via the MDACC Epic EHR system.<sup>15</sup> This data included age, 25 sex, insurance status (uninsured, Medicare, Medicaid, private insurance), and self-reported race (Black, White, Asian, American 26 Indian/Alaska Native, Native Hawaiian or other Pacific Islander [NHPI] and other/unknown) and ethnicity (Hispanic or Non-Hispanic 27 [NH]), with categories following the US Census Bureau standards. We used the Census Geocoder available through the US Census 28 Bureau website to geocode the last known patient addresses to obtain the corresponding census tracts using the Master Address 29 File/Topologically Integrated Geographic Encoding and Referencing (MAF/TIGER) database.<sup>16,17</sup> Based on the census tracts, we 30 then extracted 32 nSES variables (Listed in Appendix) from the American Community Survey (2015-2020) and 2020 decennial 31 census data.<sup>18,19</sup> These variables were selected based on those previously described <sup>20,21</sup> and those used in prior nSES indices such 32 as the Area Deprivation Index (ADI).<sup>14,22</sup> The nSES variables represent domains such as educational attainment, neighborhood 33

34 median income, poverty, crowding, race composition, home values, and essential home utilities.

1 In addition to the individual nSES variables, we also utilized the ADI as a composite measure of neighborhood socioeconomic

disadvantage. The ADI is a validated percentile rank of socioeconomic disadvantage determined at the census block group level that 2

has been used in numerous studies.<sup>23-26</sup> ADI is calculated using 17 indicators related to income level, income disparity, educational 3

attainment, employment and home values. Census block groups were ranked on the percentile scale (1-100) based on their 4

deprivation relative to the national level, with higher ADI scores indicating higher deprivation. These rankings are published by the 5 University of Wisconsin School of Medicine and Public Health.<sup>26</sup> We categorized ADI scores into guartiles to facilitate interpretation.

6

#### 7 Geospatial analysis and travel distance

Using Google Maps Geocoding API, we obtained geographic coordinates (longitude/latitude) of patient residential addresses. For 8 patients residing in Texas, the R package "googleway" was used to interface with the Google Direction API to calculate driving 9

distance (km) and time (hours) from patients' residence to MDACC at the Texas Medical Center.<sup>27</sup> To visualize the geographic 10

distribution of patient population, we aggregated the number of participants by county and ZIP Code Tabulated Area (ZCTA) and 11

created choropleth maps using "tmap" R package.<sup>28</sup> Similarly, choropleth maps were also generated to visualize and compare the 12

distributions of patients with no trial participation, non-intervention trial participation, and therapeutic trial participation, respectively. 13

We chose ZCTA as the spatial unit of visualization for the protection of patient data privacy. 14

#### **Statistical Analysis** 15

We performed descriptive analysis to examine the distribution of demographic variables for the total population and those enrolled in 16 clinical trials. We performed univariate analysis using the Chi-square test for categorical variables and a two-sample t-test for 17 continuous variables to assess the differences in clinical trial enrollment patterns by sex, race, age, histology type, insurance type, 18 nSES variables and driving distance to MDACC TMC. To address potential non-normality in our data, we included the Mann-Whitney 19 test for continuous variables, which is a non-parametric test and robust to skewed distributions. Following consideration of variables 20 of interest and independence among them, we modeled the likelihood of clinical trial participation using generalized additive logistic 21 regression. This model considered various factors such as LOD diagnosis group, age, sex, race, ADI national rank (quartiles), and 22 census tract level education attainment (% people aged 25 years and greater with less than a high school education). The model 23 included a penalized spline to accommodate the nonlinear association between participation and age. In assessing differences 24 25 across discrete variables, we employed Dunnett-adjusted contrasts, referencing specific categories for comparison. An expanded model which included interaction between age and ADI rank quantile was explored, but ruled-out due to worse Akaike Information 26 Criterion. We applied the same analytical procedure to subgroups with DLBCL and follicular lymphoma (FL) respectively. To account 27 for multiple testing of the same data among these models, we utilized adjusted alpha of 0.05/3=0.017 as the criteria for significance 28 in these models. All analyses were performed using R statistical software version 4.2.1.<sup>29</sup> 29 30

IRB approval obtained for this study denoted ICD2022-0443 31

- 32
- **Results:** 33

### 1 Patient characteristics and clinical trial participation patterns

A total of 3448 patients met the inclusion criteria of age ≥18 years with a histologically confirmed diagnosis of NHL treated at MDACC 2 between January 2017 and December 2020. Of the patients identified, 130 had international addresses, and 172 did not have 3 complete address information to be assigned to a census tract and were thus excluded from the final analysis. Therefore, the final 4 cohort consisted of 3146 patients. To assess for inadvertent selection bias, we compared the baseline characteristics between the 5 final cohort and those excluded due to incomplete address information. No significant difference was detected, except in age (median 6 age is 65 years for the study population and 68 years for the excluded patients; p-value <0.0001). There was also a notable 7 difference in the types of insurance between the study cohort and the excluded group; however, private insurance and Medicare 8 were predominant in over 90% of both cohorts. Importantly, overall clinical trial enrollment rate and the types of trials participated 9 were comparable between the excluded patients and the final study cohort, as summarized in table 2. 10

11 The study population consisted of 59.5% male and 74.9% non-Hispanic white (NHW), with 13.1% Hispanic, 6% black, and 3.7%

Asian patients. The most prevalent histology groups were DLBCL at 29.1%, Fl at 22.2%, mantle cell at 13.9%, marginal zone at 9.1%, T-cell at 8.2%, and high-grade B cell lymphoma at 6.5%. The most common insurance type was managed care (Private

14 PPO/HMO plans) at 47.8%, and Medicare at 46.2 %; 2.5% of patients were self-pay, 1.1% had Medicaid, and 2.4% had other

15 government insurance.

16 Within our cohort of 3146 patients, a subset of 1819 (58%) resided within Texas. The analysis of geographical distribution revealed

that a substantial proportion of the patients were from Harris County (N=558 [30.6%]), where the city of Houston is located (Figure 2A). Also, the map of ZCTA sample size in Harris County (Figure 2B) indicated that most patients were from suburban areas, with

19 average driving distance of 34.3 km and travel time of 30.2 minutes to the medical center. Additionally, the geographic patterns of

20 patients' residencies differed in relation to the types of trials in which patients participated, as depicted in Figure 2C-F. This suggests

- 21 that trial participation may correlate with geographic factors.
- 22

## 23 Characteristics of clinical trial participants, geospatial and univariate analysis

Clinical trial participants were 63.4% Male, 78.1% NHW, 11.6% Hispanic, 5.3% Black, and 3.1% Asian. Clinical trial participants were slightly younger than non-participants (median age 63 vs 65 years; p = 0.001). There was a high overall clinical trial participation rate of 30.3%, with the majority of patients being enrolled in therapeutic trials (20.9% of the study cohort). Patients also participated in non-interventional (12.7%) and interventional non-therapeutic (2.9%)[Table 2]. Many patients participated in more than one type of trial; thus, there was notable overlap predominantly between non-interventional and interventional therapeutic trials. There were higher participation rates among men compared with women (32.2% vs. 27.6 %; OR 1.26 p=0.006). In the total cohort, participation rates were similar across race/ethnicity. Most patients had managed care (Private HMO/PPO plans; 47%) or Medicare (45.7%) and 1 few patients had Medicaid (1.2%) or other government insurance. Participation rates did not differ by insurance type in this cohort.

2 There was significant variation in clinical trial participation by histology type (p=0.0005). The trial participation rates for DLBCL and FL

3 were 28.2% and 22% respectively. The highest trial participation rates were observed among patients with mantle cell lymphoma

4 (54.6%) and T-cell lymphoma (39.4%), which contrasted with the lower rates among patients with marginal zone lymphoma (19.2%)

- 5 and other types (10%).
- 6 In univariate analyses, 3 of the 31 nSES variables showed a significant association with clinical trial participation. Specifically, lower
- 7 participation rates were correlated with areas with a higher percentage of the overall populations living below the poverty level (p =
- 0.007), a higher percent of populations aged 19 64 living below the poverty level (p = 0.008) and a higher percent of populations
- 9 living in crowded households (more than one person per room; p = 0.002). Further analysis using the Mann-Whitney test to address
- skewed data, identified other significant associations. There are lower participation rates in areas with a higher percentage of the population over 25 years old with less than a high school diploma (p = 0.018), a lower percentage of the population over 25 with a
- population over 25 years old with less than a high school diploma (p = 0.018), a lower percentage of the population over 25 with a bachelor's degree (p = 0.048), a lower median household income (p = 0.047), a lower percentage of households with incomes above
- 12 bachelor's degree (p = 0.040), a lower median nousehold medine (p = 0.047), a lower percentage of nouseholds with medines above 13 \$200,000 (p = 0.004), and lower home values (p = 0.003). Moreover, the association between participation and ADI was significant
- 14 (p=0.043), and even stronger when analyzing only the participants in interventional/therapeutic trials (p=0.007), as summarized in
- 15 Table 2 and Table 3. Notably, there was no significant association between the racial composition of each census tract and clinical
- 16 trial participation. There was also no significant association between clinical trial participation and either driving distance (OR = 1.23;
- 17 Cl. 0.83 1.84; p= 0.31) or driving time (OR = 1.03; Cl: 0.94 1.14; p=0.52).

#### 18 Multivariable analysis

Multivariable analysis revealed a non-linear inverse correlation between increasing age and the likelihood of clinical trial participation 19 (p=0.001), indicating the odds of clinical trial participation decrease as age increases [Figure 1]. Additionally, we found histology type 20 was significantly associated with the odds of clinical trial participation. Specifically, patients with T cell lymphoma (TCL) [OR 1.62; p = 21 0.12] and mantle cell lymphoma (MCL) [OR 2.93; p < 0.001] were more likely to participate in clinical trials when compared to those 22 with DLBCL, while patients with marginal zone lymphoma had lower participation rates [OR 0.56; p =0.009] compared to DLBCL. 23 There was no significant difference in participation based on sex, race/ethnicity, ADI or the nSES variable related to education 24 25 attainment (% population aged over 25 with no high school diploma). Interestingly, the observed significant association between trial participation and ADI in univariant analysis was no longer present in the covariate-adjusted logistic regression models. In these 26 adjusted models, age appeared to show the strongest association with participation. When we adjusted the same covariates except 27 histology, a separate model for the DLBCL subgroup showed that Hispanic patients were significantly less likely to enroll in trials (OR 28 0.36; p= 0.001) than their non-Hispanic white counterparts [Figure 1b]. In the FL subgroup analysis, age demonstrated significant 29 30 inverse association with the odds of clinical trial participation (estimated degrees of freedom = 2.60; p = 0.002) [figure 1c). Regarding non-interventional trials and interventional non-therapeutic trials, the analysis revealed no significant associations across any 31 demographic, nSES variables, ADI or travel distance. The geospatial distribution of patients' residencies by trial participation is 32 33 shown in Figure 2.

2

#### 3 Discussion

It is estimated that only 2%–3% of adult cancer patients participate in clinical trials.<sup>30-35</sup> Participation rates differ significantly by care 4 setting with much higher participation rates at academic sites (~16%) compared to community sites (~7%).<sup>35</sup> It is also important to 5 note that 85% of patients receive treatment in the community, compared with only about 15% in larger academic centers.<sup>35</sup> Barriers 6 to clinical trial recruitment vary by institutional setting and a large meta-analysis found that 56% of cancer patients lacked local trial 7 availability. a significant structural barrier.<sup>35</sup> This study also found that structural factors such as trial availability and clinical factors 8 (including eligibility criteria) together precluded 77.1% of patients from having the option to participate in trials.<sup>35</sup> The under-9 representation of minority patients has been reported to be even more pronounced in hematologic malignancies with one meta-10 analysis showing that black patients represented 1.5% of participants in the Phase 3 DLBCL trials examined.<sup>34</sup> Our analysis explored 11 clinical trial enrollment patterns among patients with lymphoma at a single high-volume institution and examined the association with 12 13 race, ethnicity, and neighbor socioeconomic variables. Participation rates in our cohort were guite high across NHL subtypes with an overall clinical trial participation rate of 30% and 21% in interventional therapeutic clinical trials. Although, clinical trial participants in 14 our cohort were predominantly NHW and male, the racial composition of our cohort's trial participants largely reflected the patient 15 population treated at the institution. The only significant difference detected was among patients with DLBCL, where Hispanic 16 patients had 63% lower odds of enrolling in trials than their NHW counterparts. 17 Although we identified associations between various nSES variables and clinical trial participation, the most significant associations 18 were with age and histology. Interestingly, enrollment in clinical trials did not vary significantly by individual race or neighborhood 19 racial composition which stands in contrast to previously described lower participation rates among these groups in other studies.<sup>31,36-</sup> 20 <sup>39</sup> It is important to note that although clinical trial participation at this single center was representative of the patient population at the 21 institution, this patient population does not entirely reflect the broader population of NHL patients in the local community. There are 22 many potential reasons for the observed differences which may provide some insight into differences seen in representativeness in 23 clinical trial populations. Firstly, MDACC attracts patients from all across the globe, with approximately 43% of the new lymphoma 24 patients residing outside of Texas and 4% being international patients. It is important to note that patients who can travel to receive 25 care are likely to have more resources and less likely to live in neighborhoods with the sociodemographic characteristics that we 26

27 identified to be associated with lower clinical trial participation.

Another notable feature of our study population was that 93% of patients had private insurance or Medicare insurance, which is
 markedly different from the local community. According to U.S. Census Bureau data, Texas leads the country in the number of
 uninsured residents (18%).<sup>40</sup> Moreover, in 2020 in Harris county, 20.4% of all residents were uninsured including 26.9% of individuals
 between the ages of 19 – 64 without insurance.<sup>41,42</sup> Medicaid accounted for 15.3% of insurance coverage in Harris county, but only

1.2% of our study population had Medicaid as their primary insurance.<sup>42</sup> Other hospital systems within Harris county provide care for
 patients with other insurance types such as Harris Health that provides care for indigent, uninsured, Medicaid, and underinsured
 patients. Expanding access to clinical trials for lymphoma patients with these insurance types will require dedicated efforts to

4 increase the quantity and variety of clinical trials in the locations where these patients receive care.

A few unique features about our environment include the patient population, the staff, available resources, and the institution itself. It 5 is important to note that The Department of Lymphoma and Myeloma at MDACC is one of the largest multidisciplinary programs with 6 34 research and clinical faculty and more than 250 department members and trainees. It houses a robust portfolio of lymphoma clinic 7 trials with dozens of active therapeutic trials at any given time and dedicated programs to support clinical trial enrollment such as 8 specialized research nurse coordinator, patient navigators, and financial assistance programs. Additionally, many patients are drawn 9 to the institution specifically for novel therapies, often with specific trials in mind, which results in a patient population that is 10 inherently more inclined to participate in clinical trials. Additionally, there are specialized departments such as the behavioral science 11 and cancer health disparities, which champions several programs aimed at improving diversity of clinical trial participants and 12 13 surmounting numerous obstacles that might impede access. The institution invests in resources such as a Learning Center site, which provides information about clinical trials through various media, including education reading material and informative videos to 14 15 provide multi-media modes of information dissemination. There are also programs matching patients with similar diagnoses to facilitate peer support groups, which can help patients learn from the experiences of other patients including those previously 16 participated in trials. Lastly, there have been significant strategic investments in programs such as a growing patient navigator 17 18 program which provides trained research navigators to help patients understand clinical trial process and overcome barriers to participation including some financial challenges. 19

20

Despite its strengths, this study has other limitations. Due to the retrospective nature of our study, we were unable to control for all 21 possible confounders including selection bias arising from our eligibility criteria. Neighborhood SES may not serve as a surrogate for 22 23 individual-level SES (iSES), which measures different dimensions of social determinants of health that can also impact clinical trial participation and outcomes. Although nSES provides insight about the communities that patients come from, discrepancies between 24 iSES and nSES and complex interactions between the two are not well accounted for in our study design. These measures have 25 been shown useful when evaluated jointly and are not mutually exclusive.<sup>43-45</sup> The patient address and insurance status at time of 26 diagnosis are used as static measures but may change over the course of a patients' care, which was not captured in our analysis. 27 While we focused on primary insurance, it is important to note that many patients may have multiple insurance providers. For 28 example, patients aged 65 and older may have both Medicare and other supplementary insurance plans including Medicaid dual 29 enrollment or private insurance. Our results may not be generalizable to the US population because the highly selected patient 30 population seen at MDACC differs from patients receiving care in other healthcare settings. However, these data do indicate that in 31 clinical environments with strong infrastructure and a focus on clinical trials, similar clinical trial participation across racial and ethnic 32 groups can be achieved. 33

1 It is important to note that the current categorization of race and ethnicities and how we collect these data are intrinsically flawed.

- 2 Although self-reported race and ethnicity are generally regarded as more reliable than chart abstracted groupings, current categories
- 3 are too simplistic. Race is social construct that groups people of common ancestry by means of physical characteristics, such as hair
- 4 type, color of eyes and skin, and stature. However, these groupings, based on limited biologic basis, can have significant social
- 5 consequences. Ethnicity on the other hand refers to a large group of people with a shared culture, language, history, set
- 6 of traditions, and other features. These two concepts, though often reported together, represent very different concepts and simplify
- the categorization of diverse and heterogenous populations. For example, the current category of Asian (non-Hispanic Asian)
   inadequately captures a very diverse groups of ethnicities from various regions of a continent including people of Japanese, Chinese,
- Indian, Vietnamese heritage, to name a few, with different languages and cultures. Analogous inaccuracies occur for other groups. It
- 10 is important to interpret the results of our findings in this context.
- 11 Much of the literature about accrual to clinical trials has focused on the patient's willingness to participate. Prospective attitude
- 12 surveys and recent meta-analysis studies shown high level of willingness to participate in clinical trials that when offered the
- 13 opportunity with more than half of patients agreeing with no difference is acceptance rate by race. <sup>46 47,48</sup> Future efforts to improve
- 14 lymphoma trial participation should shift from solely focus on patient willingness to other factors. For example, programs such as the
- 15 incorporation of oncology nurse navigation have been shown to be an efficacious and cost-effective strategy for increasing clinical
- 16 participation among minority cancer patients.<sup>49</sup>
- 17 To improve enrollment rates across diverse settings, it is important to evaluate the effectiveness of potential interventions such as
- 18 financial assistance based on income level/poverty status, housing support, clinical trial educational resources and additional
- 19 counseling services. Moreover, proactively screening patients based on their address may identify patients from socioeconomically
- 20 disadvantaged neighborhoods who may benefit from these additional services. Prospectively evaluating the relationships between
- individual SES and nSES and clinical trial participation also will be important in developing future interventions.
- Academic centers with robust trial portfolios still face challenges with recruiting participants. Several studies have shown that 22 stringent eligibility criteria in lymphoma clinical trials such as criteria for stage, organ function, human immunodeficiency virus (HIV) 23 status, history of other malignancy, self-reported co-morbidity burden and other laboratory cut offs may unnecessarily exclude 24 potentially eligible patients without a significant impact on trial outcomes.<sup>50-52</sup> These criteria may preferentially exclude patients with 25 high risk disease in need of urgent treatment, older patients, or minority patients who might have a higher burden of other cancers 26 and comorbidities.<sup>53</sup> Modifications to eligibility criteria to balance between safety and access could significantly expand trial 27 accessibility, facilitate enrollment of a clinically diverse study population and ensure that patients are not unnecessarily excluded from 28 trial participation.<sup>51</sup> Recommendations to modernize eligibility criteria for cancer clinical trials have been suggested in previous 29 publications.<sup>54,55</sup> Accessibility to trial sites is another critical factor. Barriers to access comprehensive cancer centers for low-income 30 patients can be reduced by expanding coverage and clinical trials availability at community cancer centers where many receive care 31

1 or implementing decentralized clinical trials. Trial sponsors should develop policies to expand their selection of sites, taking into

2 consideration the diversity of patients treated across sites.

For future prospective trials, it will be critical to capture data on social determinants of health in order to better assess how well study populations reflect the demographics affected by a particular disease. Relying solely on race, ethnicity and currently collected demographic data may not fully capture the socioeconomic variation in clinical trial participation and neglect important factors contributing to disparities. This data will be crucial in informing future efforts and trial design considerations to ensure meaningful representation in trials. Additionally, incorporating pharmacogenomics data in future prospective trials will provide valuable insights into the efficacy of novel therapies among patients of different ancestries, offering a more nuanced understanding than the often biologically limited categories of race and ethnicity.

10 There are numerous strategies used at MDACC to improve access to clinical trials. These include systematic screening of new and return patients for trials, offering a clinical study to all new patients, the broad availability of observational and biomarker studies, and 11 the use of patient navigation for clinical trials and clinical trial nurse coordinators. It is also notable that physicians at this site have 12 trial leadership roles as principal investigators and are active in recruiting patients to clinical trials. This study shows that it is possible 13 to enroll patients across all racial/ethnic groups at rates similar to the demographics of the overall patient population, and provides 14 proof of principle for utilizing these methods. It will be important to prospectively examine the efficacy of the previously mentioned 15 strategies in improving enrollment rates of all patients and minority patients to lymphoma clinical trials and to extrapolate findings 16 from these studies to other contexts. 17

Individual- and neighborhood-level socioeconomic status have been identified as independent and joint determinants of cancer 18 disparities.<sup>3-9</sup> In this large single-center academic cohort, multivariable models identified age and diagnosis as independent predictors 19 of clinical trial participation, while race, sex, travel distance and nSES were not significant factors. Additional challenges faced by 20 potential cancer clinical trial participants such as frequent office visits and financial concerns are frequently cited as limiting factors, 21 particularly for vulnerable populations. Recognizing this deficiency, the FDA offers guidance to help achieve proportional 22 representation on clinical trials including evaluation for and elimination of restrictive eligibility criteria, increasing community 23 engagement, and decreasing financial, travel, and other burdens on participants that could be barriers to participation.<sup>56,57</sup> The 24 National Academies of Science, Engineering and Medicine 2022 report provides 17 system level recommendations with complete 25 policy assessments to improve the representation of underrepresented and excluded populations in clinical trials and achieve lasting 26 change.<sup>58</sup> These include increasing accessible and transparency of data on trial participation and recruitment efforts, journals and 27 publishers requiring information on the representativeness of trials and studies for submissions, increasing federal incentives to 28 institutions and pharmaceutical companies for increasing diversity in trials, ensuring that trials provide adequate compensation for 29 research participants, increasing the diversity of the research workforce and leadership, investing in community research 30 infrastructure as well as strategic partnerships. 31

1 Our study examined an academic institution with policies, procedures and a predominantly insured patient population. In this setting,

2 we identified age as the predominant factor associated with decreased participation in lymphoma clinical trials. Examination of multi-3 center datasets including community practices where underinsured patients received care and evaluation of interventions to improve

4 access to clinical trials are needed to fully understand and address the broader spectrum of barriers.

5

#### 6 Author Contributions:

- 7 Contribution: C.N and C.R.F conceptualized and designed the study; all authors were responsible for data acquisition; C.N., C.R.A,
- 8 A.A.A., C.X.B. and C.R.F. analyzed the data; C.N, C.R.A, L.J.N and C.R.F interpreted the data; : C.N, C.R.A, A.A.A. and L.J.N and
- 9 C.R.F drafted the manuscript; All authors critically reviewed and revised the manuscript, have approved the manuscript as submitted,
- 10 and agreed to the published version of the manuscript.
- 11
- 12 **Conflict of Interests:** The authors declare no competing financial interests.
- 13

#### 14 Acknowledgements

15 This work was supported in part by a research grant agreement with the Leukemia and Lymphoma Society IMPACT program,

16 MorphoSys US Inc (PI: Christopher R. Flowers, MD); the Cancer Prevention and Research Institute of Texas (CPRIT) [RR190079],

17 where Dr. Flowers is a CPRIT Scholar in Cancer Research; and the National Cancer Institute of the National Institutes of Health

18 under award number K24CA208132. This work was supported <u>in part</u> by a research funding from Conquer Cancer Foundation of

- 19 ASCO Young Investigator Award and ASH Minority Hematology Fellow Awards received by Chijioke Nze, MD. Additionally This work
- 20 was also supported by the Center for Community-Engaged Translational Research (CCETR), an MD Anderson resource.
- 21 Any opinions, findings, and conclusions expressed in this material are those of the authors and do not necessarily represent the

22 official views of the National Institutes of Health, American Society of Clinical Oncology®, Conquer Cancer® or the American Society

- 23 of Hematology.
- 24
- 25
- 26

4	
5	
6	
7	
8	
9	
10	
10	
11	
12	,
13	
14	
15	References
16 17 18 19 20 21 22 23	<ol> <li>Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. <i>CA Cancer J Clin</i>. Jan 2023;73(1):17-48. doi:10.3322/caac.21763</li> <li>Teras LR DC, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. 2016;66(6):443-459.</li> <li>DeRouen MC, Schupp CW, Koo J, et al. Impact of individual and neighborhood factors on disparities in prostate cancer survival. <i>Cancer Epidemiol</i>. Apr 2018;53:1-11. doi:10.1016/j.canep.2018.01.003</li> <li>Sposto R, Keegan TH, Vigen C, et al. The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. <i>Cancer Epidemiol Biomarkers Prev</i>. Jul 2016;25(7):1064-72. doi:10.1158/1055-9965.EPI-15-1326</li> <li>Cheng I, Shariff-Marco S, Koo J, et al. Contribution of the neighborhood environment and obesity to breast cancer survival: the California</li> </ol>
24	Breast Cancer Survivorship Consortium. Cancer Epidemiol Biomarkers Prev. Aug 2015;24(8):1282-90. doi:10.1158/1055-9965.EPI-15-0055

2

3

1 6. Gomez SL, Shariff-Marco S, DeRouen M, et al. The impact of neighborhood social and built environment factors across the cancer

- 2 continuum: Current research, methodological considerations, and future directions. *Cancer*. Jul 15 2015;121(14):2314-30.
- 3 doi:10.1002/cncr.29345

Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the
 modern treatment era. *Blood*. Jun 5 2014;123(23):3553-62. doi:10.1182/blood-2013-07-517110

B. DeRouen MC, Yang J, Jain J, Weden MM, Gomez SL, Shariff-Marco S. Disparities in prostate cancer survival according to neighborhood
 archetypes, a population-based study. *Urology*. Jul 22 2021;doi:10.1016/j.urology.2021.05.085

Aoki RF, Uong SP, Gomez SL, et al. Individual- and neighborhood-level socioeconomic status and risk of aggressive breast cancer
 subtypes in a pooled cohort of women from Kaiser Permanente Northern California. *Cancer*. Aug 20 2021;doi:10.1002/cncr.33861

10 10. Murthy VH KH, Gross CP. Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities. JAMA. 2004;291(22):2720–2726.

11 11. Gopishetty S KV, Guddati AK. Age and race distribution in patients in phase III oncology clinical trials. *Am J Transl Res*. September 15 2020;12(9):5977-5983.

12. Casey M, Odhiambo L, Aggarwal N, Shoukier M, Islam KM, Cortes J. Representation of the population in need for pivotal clinical trials in 14 lymphomas. *Blood*. Aug 31 2023;142(9):846-855. doi:10.1182/blood.2023020052

- 15 13. Kozlov M. FDA to require diversity plan for clinical trials. *Nature*. Feb 16 2023;doi:10.1038/d41586-023-00469-4
- 16 14. Kind AJ, Jencks S, Brock J, et al. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study.
- 17 Ann Intern Med. Dec 2 2014;161(11):765-74. doi:10.7326/M13-2946
- 18 15. Corporation E. Epic electronic medical record [Software]. 2023.

19 16. Master Address File/Topologically Integrated Geographic Encoding and Referencing (MAF/TIGER) database

20 17. Geocoder. C. Accessed December 5, 2023.

21 , https://geocoding.geo.census.gov/geocoder/

- 18. Bureau USC. American Community Survey 5-year Public Use Microdata Samples [SAS Data file]. . In: file] SD, editor. 2020.
- 23 19. c USCB. US Decennial Census 2020. https://data.census.gov/cedsci/

24 20. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic

- 25 groups. *Cancer Causes Control*. Oct 2001;12(8):703-11. doi:10.1023/a:1011240019516
- 26 21. Gomez SL, Glaser SL, McClure LA, et al. The California Neighborhoods Data System: a new resource for examining the impact of

27 neighborhood characteristics on cancer incidence and outcomes in populations. *Cancer Causes Control*. Apr 2011;22(4):631-47.

#### 28 doi:10.1007/s10552-011-9736-5

29 22. Singh GK. Area deprivation and widening inequalities in US mortality, 1969-1998. *Am J Public Health*. Jul 2003;93(7):1137-43.

- 30 doi:10.2105/ajph.93.7.1137
- Fairfield KM, Black AW, Ziller EC, et al. Area Deprivation Index and Rurality in Relation to Lung Cancer Prevalence and Mortality in a Rural
   State. JNCI Cancer Spectr. Aug 2020;4(4):pkaa011. doi:10.1093/jncics/pkaa011

33 24. Ghirimoldi FM, Schmidt S, Simon RC, et al. Association of Socioeconomic Area Deprivation Index with Hospital Readmissions After Colon

34 and Rectal Surgery. J Gastrointest Surg. Mar 2021;25(3):795-808. doi:10.1007/s11605-020-04754-9

1 25. Lau N, Bradford MC, Steineck A, et al. Examining key sociodemographic characteristics of adolescents and young adults with cancer: A post hoc analysis of the Promoting Resilience in Stress Management randomized clinical trial. Palliat Med. Mar 2020;34(3):336-348. 2 3 doi:10.1177/0269216319886215 Center for Health Disparities Research UoWSoMPH. 2015 Area Deprivation Index, version 2.0. Accessed October 15, 2022, 4 26. 5 https://www.neighborhoodatlas.medicine.wisc.edu/ 6 27. googleway: Accesses Google Maps APIs to Retrieve Data and Plot Maps. 2022. https://CRAN.R-project.org/package=googleway 7 28. M T. tmap: Thematic Maps in R. Journal of Statistical Software. 2018;84(6):1 - 39. doi:10.18637/jss.v084.i06 8 29. *R*: A Language and Environment for Statistical Computing. 9 30. Tejeda HA GS, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. 88(12):812-816. 10 11 31. Sateren WB TE, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to 12 cancer treatment trials. J Clin Oncol. 2002;20(8):2109-2117. 13 32. Murthy VH KH, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. 2004;291(22):2720–2726. 14 33. ransforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. 2010; 15 34. Gopishetty S KV, Guddati AK. Age and race distribution in patients in phase III oncology clinical trials. September 2020:5977-5983. Joseph M Unger RV, Dawn L Hershman, Lori M Minasian, Mark E Fleury. Systematic Review and Meta-Analysis of the Magnitude of 16 35. 17 Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. March 2019;111(3):245–255. 18 36. Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. JAMA Oncol. Jan 2016;2(1):137-9. doi:10.1001/jamaoncol.2015.3924 19 20 37. Sharrocks K, Spicer J, Camidge DR, Papa S. The impact of socioeconomic status on access to cancer clinical trials. Br J Cancer. Oct 28 21 2014;111(9):1684-7. doi:10.1038/bjc.2014.108 Du XL, Fang S, Meyer TE. Impact of treatment and socioeconomic status on racial disparities in survival among older women with breast 22 38. 23 cancer. Am J Clin Oncol. Apr 2008;31(2):125-32. doi:10.1097/COC.0b013e3181587890 24 Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients 39. 25 With Cancer. Cancer Control. Oct 2016;23(4):327-337. doi:10.1177/107327481602300404 26 Bureau USC. Decline in Share of People Without Health Insurance Driven by Increase in Public Coverage in 36 States. 40. 27 https://www.census.gov/library/stories/2022/09/uninsured-rate-declined-in-28-states.html 28 American community survey S2701: SELECTED CHARACTERISTICS OF HEALTH INSURANCE COVERAGE IN THE UNITED STATES. 41. https://data.census.gov/cedsci/table?g=health%20insurance%20coverage&g=0100000US 0500000US48201&tid=ACSST5Y2020.S2701. 29 30 42. Small Area Health Insurance Estimates (SAHIE). https://www.census.gov/datatools/demo/sahie/#/?s statefips=48&s year=2020&s stcou=48201&s racecat=0&s agecat=1&s measures=ui snc. 31 32 43. Cheng E, Soulos PR, Irwin ML, et al. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With

Nonmetastatic Common Cancers. JAMA Netw Open. Dec 1 2021;4(12):e2139593. doi:10.1001/jamanetworkopen.2021.39593 33

Ribeiro AI, Fraga S, Severo M, et al. Association of neighbourhood disadvantage and individual socioeconomic position with all-cause
 mortality: a longitudinal multicohort analysis. *Lancet Public Health*. May 2022;7(5):e447-e457. doi:10.1016/S2468-2667(22)00036-6

3 45. Wallar LE, Rosella LC. Individual and neighbourhood socioeconomic status increase risk of avoidable hospitalizations among Canadian

4 adults: A retrospective cohort study of linked population health data. Int J Popul Data Sci. Sep 1 2020;5(1):1351. doi:10.23889/ijpds.v5i1.1351

5 46. Unger JM HD, Till C, Minasian LM, Osarogiagbon RU, Fleury ME, Vaidya R. "When Offered to Participate": A Systematic Review and Meta-

6 Analysis of Patient Agreement to Participate in Cancer Clinical Trials. 2021;113(3)

7 47. *HINTS Brief 48: Clinical Trial Participation Among U.S. Adults*. March 2022.

8 48. Comis RL MJ, Aldigé CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. 2003;21(15)

9 49. Holmes DR, Major J, Lyonga DE, Alleyne RS, Clayton SM. Increasing minority patient participation in cancer clinical trials using oncology 10 nurse navigation. *Am J Surg*. Apr 2012;203(4):415-22. doi:10.1016/j.amjsurg.2011.02.005

150. Luan D FT, Toure A, Flowers CR, Link B, Friedberg JW, Cohen JB, Kahl B, Lossos IS, Nastoupil L, Maurer MJ, Cerhan JR, Martin P. Evaluating 12 the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis. 2022;6(15)

13 51. Harkins RA PS, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum KA, Cashen AF, Casulo C, Friedberg JW, Johnston PB, Kahl BS,

14 Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan PM, Westin JR, Koff JL, Flowers CR. Improving eligibility criteria for

15 first-line trials for patients with DLBCL using a US-based Delphi-method survey. 2022;6(9)

16 52. Khurana A MR, Nowakowski GS, Habermann TM, Ansell SM, LaPlant BR, Link BK, Cerhan JR, Maurer MJ, Witzig TE. Impact of Organ

17 Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? 2021;39(15)

18 53. Khurana A MA, Nastoupil LJ, Reagan PM, Farooq U, Romancik JT, McDonnell TJ, Riska SM, Lossos IS, Kahl BS, Martin P, Witzig TE, Cerhan

19 JR, Flowers CR, Maurer MK, and Nowakowski GS Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical

20 Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis [abstract 850]. 2022;

21 54. ASCO in Action: Initiative to Modernize Eligibility Criteria for Clinical Trials Launched. 2016;

22 55. Kim ES BS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical

23 Oncology and Friends of Cancer Research Joint Research Statement. 2017;35(33):3737–3744.

24 56. Administration TUFaD. Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in

25 Clinical Trials; Draft Guidance for Industry; Availability. 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-

26 <u>documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations</u>

27 57. Enhancing the Diversity of Clinical Trial Populations - Eligibility Criteria, Enrollment Practices adn Trial Designs: Guidance for Industry.
 28 November 2020.

29 58. National Academies of Sciences E, and Medicine. Improving Representation in Clinical Trials and Research: Building Research Equity for

30 Women and Underrepresented Groups. In: Bibbins-Domingo K, Helman A, eds. Improving Representation in Clinical Trials and Research: Building

31 Research Equity for Women and Underrepresented Groups. 2022. The National Academies Collection: Reports funded by National Institutes of

32 Health.

33

## **Tables**

2	Table 1:	Patient	characteristics	and census	tract level nSES.
---	----------	---------	-----------------	------------	-------------------

1

	Total	White	Hispanic	Black	Asian	Other/Unknown
Ν	3146	2356 (74.9%)	411 (13.1%)	189 (6%)	116 (3.7%)	74 (2.4%)
Gender						
Female	1274	913 (71.7 %)	175 (13.7 %)	93 (7.3%)	57 (4.5 %)	36 (2.8%)
Male	1872	1443 (77.1%)	236 (12.6%)	96 (5.13%)	59 (3.1%)	38 (2%)
Age						
Mean (SD)	62.6 (14.6)	64.2 (13.9)	57.4 (15.7)	57.8 (15.6)	57.9 (16.5)	60.2 (13.3)
Median	64.6	66.2	59.1	59.3	60.3	60.8
Range	18.1 - 100.7	18.6 - 100.7	18.1 - 96.2	21.9 - 98.6	18.7 - 91.3	30.4 - 83.2
Diagnosis						
DLBCL	917	642 (70 %)	143 (15.6%)	65 (7.1%)	47 (5.1%)	20 (2.2%)
FL	698	540 (77.4%)	87 (12.5%)	34 (4.9%)	20 (2.9%)	17 (2.4%)
MCL	417	364 (87.3%)	28 (6.7%)	8 (1.9%)	6 (1.44%)	11 (2.6%)
MZL	287	214 (74.6%)	36 (12.5%)	18 (6.3%)	9 (3.1%)	10 (3.5%)
TCL	259	164 (63.3%)	43 (16.6%)	33 (12.7%)	13 (5%)	6 2.3%)
Misc.	235	191 (81.3%)	19 (8.1%)	14 (6%)	5 (2.1%)	6 (2.6%)
High Grade BCL	205	141 (68.8%)	42 (20.5%)	8 (3.9%)	11 (5.4 %)	3 (1.5%)
Composite	118	91 (77.12%)	13 (11%)	9 (7.6%)	4 (3.4%)	1 (0.9 %)
Grey Zone Lymphoma	10	9 (90 %)	0 (0%)	0 (0%)	1 (10 %)	0 (0%)
ADI (Quartiles)						
Q1 (0 – 25)	774	615 (79.5 %)	52 (6.7%)	23 (3%)	58 (7.5 %)	26 (3.4%)
Q2 (26 – 50)	889	700 (78.7%)	97 (10.9%)	48 (5.4%)	30 (3.4%)	14 (1.6%)
Q3 (51 – 75)	753	544 (73.6%)	123 (16.3%)	52 (6.9%)	14 (1.9%)	20 (2.7%)
Q4 (76 – 100)	472 (16.3%)	295 (62.5%)	112 (23.7%)	52 (11%)	5 (1.1%)	8 (1.7%)
ADI (Continuous)						
Range	1 - 100	1 - 100	2- 100	1 - 100	1 - 93	1 - 95

Mean (SD)	45.5 (26.2)	43.4 (25.4)	57.2 (25.8)	57.9 (26)	30.2 (23.1)	39.8 (27.1)
Median	44	41	59.5	58	22	38

## **Table 2.** Population Differences: Study Cohort vs. Excluded Patients and Clinical Trial Participants vs. Non-participants

	Excluded NHL	Total study	p-value	<b>Clinical Trial</b>	Non-	p-value
	Lacking	cohort	$\alpha = 0.05)$	Participants	participants	(α = 0.05)
	census tract	population		(%)	(%)	
	(%)					
Ν	172	3146		950 (30.2)	2196 (69.8)	
Gender						
Female	74 (43)	1274 (40.5)	0.52	348 (36.6)	926 (42.2)	0.004
Male	98 (57)	1872 (59.5)	0.52	602 (63.4)	1270 (57.8)	0.004
Age						
Mean	67	63		61	63	
SD	11.1	14.6	<0.0001	14.2	14.7	0.002
Median	68	65		63	65	
Ethnicity						
Hispanic/Latino	25 (14.5)	411 (13.1)		110 (11.6)	301 (13.7)	
Non-Hispanic (NH)	143 (83.1)	2660 (84.6)	0.90	822 (86.5)	1838 (83.7)	0.12
Unknown	4 (2.3)	75 (2.4)		18 (1.9)	57 (2.6)	
Race						
NH White	132 (76.7)	2356 (74.9)		742 (78.1)	1614 (73)	
Hispanic/Latino	25 (14.5)	411 (13.1)		110 (11.6)	301 (13.7)	
NH Black/AA	8 (4.7)	189 (6)	0.40	50 (5.3)	139(6.3)	0.11
NH Asian	2 (1.2)	116 (3.7)		29 (3.1)	87 (3)	
Other/Unknown	5 (2.9)	74 (2.4)		19 (2)	55 (2.5)	
Diagnosis						
DLBCL	55 (32)	917 (29.1)	0.89	259 (27.3)	658 (30.0)	0.0005
FL	41 (23.8)	698 (22.2)		154 (16.2)	544 (24.8)	0.0005

MCL	18 (10.5)	417 (13.3)		228 (24)	189 (8.6)	
MZL	16 (9.3)	287(9.1)		55 (5.8)	214 (10.6)	
TCL	16 (9.3)	259 (8.2)		102 (10.7)	157 (7.1)	
Misc.	12 (7)	235 (7.5)		49 (5.2)	186 (8.5)	
High Grade BCL	8 (4.7)	205 (6.5)		63 (6.6)	142 (6.5)	
Composite	6 (3.5)	118 (3.8)		39 (4.1)	79 (3.6)	
Grey Zone Lymphoma	0 (0)	10 (0.3)		1 (0.1)	9 (0.4)	
Clinical Trial Type						
Any	50 (29.1)	950 (30.2)	0.95	950 (30.2)	N/A	
Non-interventional	19 (11)	403 (12.8)	0.8	403 (12.8)	N/A	
Interventional, non- therapeutic	3 (1.7)	90 (2.9)	0.69	90 (2.9)	N/A	
Interventional, Therapeutic	35 (20.3)	646 (20.5)	0.92	646 (20.5)	N/A	
Insurance type						
Private insurance / Managed Care	68 (39.5)	1504 (47.8)		472 (49.7)	1032 (47)	
Medicare	101 (58.7)	1452 (46.2)	6.2)	425 (44.7)	1027 (46.8)	0.40
Medicaid	0 (0)	36 (1.1)	0.011	11 (1.2)	25 (1.1)	
Self-pay	0 (0)	80 (2.5)		18 (1.8)	62 (2.8)	
Government/Other	3 (1.7)	74 (2.4)		24 (2.5)	50 (2.3)	
Area Deprivation Index (Quartiles)				N= 879	N = 2009	
Q1 (0 – 25)	N/A	N/A		260 (29.6)	514 (25.6)	
Q2 (26 – 50)	N/A	N/A	N/A	279 (31.7)	610 (30.4)	0 043
Q3 (51 – 75)	N/A	N/A	N/A	208 (23.7)	545 (27.1)	0.045
Q4 (76 – 100)	N/A	N/A		132 (15)	340 (16.9)	
Area Deprivation Index (Continuous)						
Mean	N/A	N/A	NI / A	44	46	0.000
<u></u>						

Median	N/A	N/A	42	45	

1 Bold values denote statistical significance at the P < .05 level.

2 DLBCL: Diffuse B Cell Lymphoma. FL: Follicular Lymphoma. MCL: Mantle Cell Lymphoma. MZL: Marginal zone Lymphoma

3 TCL: T-Cell Lymphoma. NH: Non-Hispanic. High grade BCL: High Grade B- Cell Lymphoma

4

5 Table 3. Comparison of demographic factors between non-participates vs participation by type of trial

	Non- participants (%)	Interventional therapeutic trial all (%)	p-value (α = unadjusted)	Interventional Non- therapeutic only	p-value (α = unadjusted	Non- interventional Trial only	p-value (α = unadjusted
Ν	2196	646		69		235	
Gender							
Female	926 (42.2)	228 (35.3)	0.75	33 (47.8)	0.20	87 (37)	0.91
Male	1270 (57.8)	418 (64.7)	0.75	36 (52.2)	0.39	148 (63)	0.81
Age							
Mean	63	61		60		63	
SD	14.7	13.3	0.001	14.6	0.062	16.4	0.86
Median	65	62		62		65	
Ethnicity							
Hispanic/Latino	301 (13.7)	74 (11.5)		8 (11.6)		28 (11.9)	
Non-Hispanic (NH)	1838 (83.7)	560 (86.7)	0.17	60 (87)	0.74	202 (86)	0.67
Unknown	57 (2.6)	12 (1.9)		1 (1.4)		5 (2.1)	
Race							
NH White	1614 (73)	505 (78.2)		55 (79.7)		182 (77.4)	
Hispanic/Latino	301 (13.7)	74 (11.5)		8 (11.6)		28 (11.9)	
NH Black/AA	139 (6.3)	33 (5.1)	0.22	4 (5.8)	0.63	13 (5.5)	0.76
NH Asian	87 (3)	20 (3.1)		2 (2.9)		7 (3)	
Other/Unknown	55 (2.5)	14 (2.2)		0 (0)		5 (2.1)	

Diagnosis							
DLBCL	658 (30.0)	162 (25)		18 (26)		79 (33.6)	
FL	544 (24.8)	114 (17.6)		21 (30.4)		19 (8.1)	
MCL	189 (8.6)	207 (32)		4 (5.8)		17 (7.2)	
MZL	214 (10.6)	24 (3.7)		10 (14.5)		21 (8.9)	
TCL	157 (7.1)	79 (12.2)	0.0005	4 (5.8)	0.58	19 (8.1)	0.0005
Misc.	186 (8.5)	10 (1.5)		8 (11.6)		31 (13.2)	
High Grade BCL	142 (6.5)	26 (4)		4 (5.8)		33 (14)	
Composite	79 (3.6)	23 (3.6)		0 (0)		16 (6.8)	
Grey Zone Lymphoma	9 (0.4)	1 (0.2)		0 (0)		0 (0)	
Insurance type							
Private insurance / Managed Care	1032 (47)	332 (51.4)		40 (58)		100 (42.6)	
Medicare	1027 (46.8)	278 (43)	0.37	28 (40)		119 (50.6)	0.19
Medicaid	25 (1.1)	7 (1.1)		0 (0)	0.25	4 (1.7)	
Self-pay	62 (2.8)	14 (2.2)		1 (1.4)		3 (1.3)	
Government/Other	50 (2.3)	15 (2.3)		0 (0)		9 (3.8)	
Area Deprivation Index (Quartiles)	N = 2009	N= 598				N = 219	
Q1 (0 – 25)	514 (25.6)	191 (31.9)		18 (29)		51 (23.3)	
Q2 (26 – 50)	610 (30.4)	185 (30.9)	0.007	20 (32.2)	0.95	74 (33.8)	0.52
Q3 (51 – 75)	545 (27.1)	141 (23.6)	0.007	14 (22.6)	0.85	53 (24.2)	0.52
Q4 (76 – 100)	340 (16.9)	81 (13.5)		10 (16.1)		41 (18.7)	
Area Deprivation Index (Continuous)							
Mean	46	42		44		47.3	
SD	26.2	25.9	0.001	26	0.54	26.5	0.86
Median	45	41		40		44	

1 Bold values denote statistical significance at the P < .05 level.

2 DLBCL: Diffuse B Cell Lymphoma. FL: Follicular Lymphoma. MCL: Mantle Cell Lymphoma. MZL: Marginal zone Lymphoma

3 TCL: T-Cell Lymphoma. NH: Non-Hispanic. High grade BCL: High Grade B- Cell Lymphoma

1	Figure titles and legends
2	Figure 1: Depiction of trial participation by age. A) Entire study cohort B. DLBCL sub-cohort. C.) FL sub-cohort.
3	
4	Figure 2. Geospatial distribution of patients' residencies by trial participation.
5 6	Legend: A. Distribution of all patients within Texas; B. All patients proximate to TMC; C. Patients with any trial participation; D. Patients with no trial participation; E. Patients in non-interventional trials (with overlap); F. Patients in therapeuric trials.
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	

# Figure 1



## Figure 2

